CN102247416B - Blood lipid lowering application of total saponins of panax japonicus - Google Patents
Blood lipid lowering application of total saponins of panax japonicus Download PDFInfo
- Publication number
- CN102247416B CN102247416B CN 201010176635 CN201010176635A CN102247416B CN 102247416 B CN102247416 B CN 102247416B CN 201010176635 CN201010176635 CN 201010176635 CN 201010176635 A CN201010176635 A CN 201010176635A CN 102247416 B CN102247416 B CN 102247416B
- Authority
- CN
- China
- Prior art keywords
- total saponins
- panax japonicus
- japonicus total
- group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a blood lipid lowering application of total saponins of panax japonicus. The total saponins of panax japonicus can be mixed with a pharmaceutically acceptable carrier.
Description
Technical field
The blood fat reducing purposes that relates to panax japonicus total saponins of the present invention.
Background technology
Hyperlipemia (hyperlipidemias) mainly is to raise with cholesterol in the blood plasma (TC), triglyceride (TG), low density lipoprotein, LDL (LDL-C), high density lipoprotein (HDL-C) is reduced to a kind of metabolism disorder of blood lipid state of performance, and it is the important risk factor that the cardiovascular and cerebrovascular diseases such as atherosclerosis (AS) and coronary heart disease (CHD) occur.Blood fat reducing can delay the progress of AS, and then reduces incidence rate and the mortality rate of cardiovascular and cerebrovascular disease.Cholesterol reducing (TC) can make the dangerous corresponding reduction of coronary heart disease.Though the number of chemical medicine has clear and definite effect for reducing fat at present, prolonged application has side effect in various degree more.Such as the statins long-term prescription, very easily cause hepatic injury, so the research and development curative effect new Chinese medicine that toxic and side effects is low certainly is significant.
The traditional Chinese medical science thinks, hyperlipidemia is mainly by qi depression to blood stasis with stagnation of QI expectorant is turbid causes, and normal by the ventilation blood stasis dispelling clinically, the turbid descending reduces phlegm and carries out determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs.In medication, the traditional Chinese medical science often adopts the dual-purpose medical material of natural medicine-food, and to have an effect for reducing fat definite because of it, and toxic and side effects is little, and material obtains and the advantage such as low price easily, is subject to gradually people and payes attention to.Yet the Chinese medicine for the treatment of hyperlipidemia usually is the numerous decoction of flavour of a drug, takes and carries equal inconvenience.The Chinese patent medicine that comes from a large number decoction also is difficult to control quality because flavour of a drug are numerous.Therefore, people's expectation is found out single safely and effectively active site or activated monomer by the research to Chinese medicine from plant, be used for the treatment of hyperlipidemia.
Rhizoma Panacis Japonici is the dry root of Araliaceae Panax herbaceos perennial Panax japonicus C1 A1 Mey1.Former is a kind of famous and precious Chinese herbal medicine among the people, has now recorded in the Pharmacopoeia of the People's Republic of China the similar Radix Ginseng of medicinal function and Radix Notoginseng.Rhizoma Panacis Japonici is born in by hillside limes marginis, dark and damp area or the rock ditch ravine.Mainly be distributed in the ground such as Guizhou, Hunan, Yunnan, Anhui, Jiangxi, Hubei.Excavate annual autumn, removes stem and leaf, tells fleshy tap root, and rhizome is removed crust, dries or dry in the shade and can be used as medicine.Supplementary Amplifications of the Compendium of Materia Medica begins to be stated from.Sweet, the little hardship of Rhizoma Panacis Japonici, temperature.Have the multiple efficacies such as blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, strengthening by means of tonics.The strengthening by means of tonics effect of existing similar Radix Ginseng has again eliminating stasis to stop pain, hemostasis, the phlegm-dispelling functions of similar Radix Notoginseng, be mainly used in weak after being ill, chronic cough hemoptysis, cough with copious phlegm, traumatic injury.Rhizoma Panacis Japonici contains multiple saponin, volatile oil, saccharide and several amino acids.
The technical problem to be solved in the present invention is the blood fat reducing purposes of research panax japonicus total saponins.For addressing the above problem, provide technical scheme as follows.
The utilization of panax japonicus total saponins aspect blood fat reducing.
The utilization of described blood fat reducing aspect comprises atherosclerosis that hyperlipidemia and hyperlipidemia are caused and prevention and the treatment of coronary heart disease.
Described compositions comprises panax japonicus total saponins and pharmaceutically acceptable carrier or conventional edible adjuvant.
The present invention has significant reducing effect to TG, TC and the LDL-C of hyperlipidemia laboratory animal, and HDL-C is had significant rising effect.The present invention includes with panax japonicus total saponins and mix with pharmaceutically acceptable carrier.
Pharmaceutically acceptable carrier comprises the adjuvant of oral formulations adjuvant or parenteral administration.Route of administration can be oral, injection, topical etc.According to technical scheme of the present invention, said composition can be oral formulations or injection preparation, and wherein oral formulations comprises capsule, soft capsule, granule, oral liquid, tablet, drop pill etc.Used adjuvant comprises: the conventional adjuvants such as starch, sucrose, lactose, Icing Sugar, glucose, mannitol, xylitol, Polyethylene Glycol, isopropyl alcohol, tween 80, glycerol, propylene glycol, microcrystalline Cellulose sodium, dextrin, cyclodextrin, sodium chloride, vitamin C, cysteine, citric acid, sodium thiosulfate, sodium sulfite, stearate and gelatin, preparation later stage preparation technology and equipment all belong to the routine techniques of pharmaceutical field, the present invention is not construed as limiting this, so will not describe in detail at this.
The dosage of present composition oral administration is 2-3 times/day, 0.25～0.50g/ time.
Panax japonicus total saponins extract of the present invention is to extract to obtain from natural Chinese medicine Rhizoma Panacis Japonici, and Rhizoma Panacis Japonici is the Chinese herbal medicine of commonly using, and long-term traditional Chinese medical science medication experience is arranged, and this medicine is safe to use, puts down in writing without the overt toxicity effect.
Panax japonicus total saponins has definite reduction hyperlipidemia laboratory animal TG, TC and the significance effect of LDL-C, has the significance effect of rising HDL-C, and does not have liver toxicity, cuts down his phasing to safety than suffering.Therefore, panax japonicus total saponins has the prospect that is developed to fat-reducing medicament.
Embodiment one
The preparation of panax japonicus total saponins
The extraction of panax japonicus total saponins, purification and preparation: get the Rhizoma Panacis Japonici coarse powder, add 60% ethanol of 10 times of amounts, soaked 2 hours, water-bath reflux, extract, 2 hours, filtration gets filtrate.Medicinal residues are used 60% the alcohol reflux 2 times of 10 times of amounts again, each 2 hours, filter.Merge 3 times filtrate, decompression recycling ethanol is to distinguishing the flavor of without alcohol, and be mixed with medical material: medicinal liquid (g/ml) is 1: 1 solution.On the HPD-100 macroporous resin column handled well, water, 60% ethanol elution.Merge 60% ethanol elution, reclaim solvent and do near, through 65 ℃ of drying under reduced pressure, obtain panax japonicus total saponins.
Embodiment two
The lipid-lowering test of panax japonicus total saponins
1. experiment material
1.1 medicine and reagent: 0.5%CMC-Na solution, the mouse stomach needle tubing, centrifuge tube, some of Fresh Eggs, simvastatin sheet (Shanghai Xinyi Wanxiang Pharmaceutical Co., Ltd., lot number: 080201), Xuezhikang glue is assisted (Beijing WBL Peking University Biotech Co., Ltd, lot number: 20080708), triglyceride determination test kit (the safe clinical reagent company limited of Beijing Northization, lot number: 20080610), T-CHOL test kit (the safe clinical reagent company limited of Beijing Northization, lot number: 20080610), low-density LP determination reagent box (the safe clinical reagent company limited of Beijing Northization, lot number: 20080610).Panax japonicus total saponins (Z1) is the self-control of this laboratory.
1.2 experiment key instrument: TDL80-2B type low speed centrifuge, microplate reader, TGL-16 high speed tabletop refrigerated centrifuge.
1.3 laboratory animal: Kunming mouse, male and female half and half, body weight 18-22g.
2. test liquid sample
The panax japonicus total saponins of preparation among the embodiment one.
3. the preparation of test specimen liquid
3.175% egg-nog solution preparation: get some of Fresh Eggs, the bottom is opened an osculum and is vacated Ovum Gallus domesticus album, egg yolk 2 is put down gently in empty beaker. and needle tubing is probeed in the egg yolk thin film, draw egg yolk liquid, put in the graduated cylinder of 100ml, measure the 75ml egg yolk liquid, to scale, use magnetic stirrer egg-nog solution 10 minutes with normal saline dilution, make egg-nog solution even, reduce error, prepare during modeling temporarily.
3.2 the preparation of each test sample liquid:
3.2-1.CMC-Na the preparation of solution: precision takes by weighing 5gCMC-Na, the 1000mL distilled water is mixed with concentration and is 0.5% CMC-Na solution.
3.2-2. the preparation of Xuezhikang medicinal liquid: precision takes by weighing the 5g content, with the 0.5%CMC-Na suspendible, is settled to 100ml, and being mixed with concentration is the medicinal liquid sample of 0.05g/ml.
3.2-3. the preparation of simvastatin medicinal liquid: precision takes by weighing 14g simvastatin sheet (containing simvastatin 70mg), the 100ml0.5%CMC-Na suspendible, and being made into concentration is 0.0007g/ml medicinal liquid sample.
3.2-4. the preparation of high dose panax japonicus total saponins medicinal liquid: precision takes by weighing the 1.5g panax japonicus total saponins.The 100ml0.5%CMC-Na suspendible, being mixed with concentration is the medicinal liquid sample of 0.015g/ml.
3.2-5. the preparation of low dosage panax japonicus total saponins medicinal liquid: precision takes by weighing the 0.75g panax japonicus total saponins, the 100ml0.5%CMC-Na suspendible, and being mixed with concentration is the medicinal liquid sample of 0.0075g/ml.
4. experimental technique
72 of Kunming mouses, 18-22g, male and female half and half are divided into 6 groups at random, 12 every group.Be divided into normal blank group, hyperlipidemia model group, simvastatin positive controls, Xuezhikang positive controls, panax japonicus total saponins high dose group, the panax japonicus total saponins low dose group.Gastric infusion.Normal group and hyperlipidemia model group are pressed 0.2ml/10g gavage 0.5%CMCNa every day, administration group gavage every day gives the relative medicine of 0.2ml/10g volume, and dosage is respectively: the Xuezhikang matched group is that 1g/kg, simvastatin matched group are that 0.014g/kg, panax japonicus total saponins high dose group are that 0.3g/kg, panax japonicus total saponins low dose group are 0.15/kg.Administration is 14 days altogether.Last administration is after 2 hours, and each is organized equal lumbar injection 75% egg-nog normal saline solution 0.2ml/10g and causes experimental hyperlipidemia.After the mice modeling 20 hours, adopt and pluck the eyeball blood collection method, centrifugalize serum, according to T-CHOL, triglyceride, low density lipoprotein, LDL, high density lipoprotein test kit description operates, and measures respectively the content of TC, TG, LDL-C and HDL-C.Experimental result is shown in following table 1-4.
The experimental result that table 1. panax japonicus total saponins (Z1) affects TG (X ± SD)
Annotate:
*Representation model has been compared significant difference with blank,
*Representation model has been compared utmost point significant difference with blank.
▲Represent that each administration group compared significant difference with model group,
▲ ▲Represent that each administration group compared utmost point significant difference with model group.Together lower.
The experimental result that table 2. panax japonicus total saponins (Z1) affects TC (X ± SD)
The experimental result that table 3. panax japonicus total saponins (Z1) affects LDL-C (X ± SD)
The experimental result that table 4. panax japonicus total saponins (Z1) affects HDL-C (X ± SD)
5. result and discussion
Model is compared with the blank group, and the concentration of TG, TC, LDL-C all has utmost point significance to raise (p＜0.01), and HDL-C concentration has significance to reduce (p＜0.05), and the result shows laboratory animal modeling success.Aspect the concentration change of TG, to compare with model group, Xuezhikang group, simvastatin group, panax japonicus total saponins high dose group all have utmost point significance reducing effect (p＜0.01); The panax japonicus total saponins low dose group has significance reducing effect (p＜0.05).Aspect the concentration change of TC, to compare with model group, simvastatin group, panax japonicus total saponins high dose group all have utmost point significance reducing effect (p＜0.01); And Xuezhikang group, panax japonicus total saponins low dose group have significance reducing effect (p＜0.05).Aspect the concentration change of LDL-C, compare with model group, Xuezhikang group, simvastatin group, panax japonicus total saponins high dose group all have utmost point significance reducing effect (p＜0.01), and the panax japonicus total saponins low dose group has significance reducing effect (p＜0.05).Aspect the concentration change of HDL-C, compare with model group, the panax japonicus total saponins high dose group, utmost point significance rising effect (p＜0.01) is arranged, and panax japonicus total saponins low dose group, simvastatin group, have significance rising effect (p＜0.05), the Xuezhikang group does not have significance rising effect.
Experimental result shows that panax japonicus total saponins has definite reduction hyperlipidemia laboratory animal TG, TC and the significance effect of LDL-C, and the significance effect of rising HDL-C is arranged, and has the prospect that is developed to fat-reducing medicament.
Embodiment three
Panax japonicus total saponins and simvastatin cause the hepatic injury toxic and side effects relatively
1. experiment material
1.1 medicine and reagent
Simvastatin sheet (Shanghai Xinyi Wanxiang Pharmaceutical Co., Ltd., lot number: 080201), glutamate pyruvate transaminase (ALT) the detection kit (glad biotechnology research institute of Shanghai section, lot number 20090401), glutamic oxaloacetic transaminase, GOT (AST) the detection kit (glad biotechnology research institute of Shanghai section, lot number 20090301).
1.2 experimental apparatus
721 spectrophotometers (Shanghai essence instrument plant), LXJ-II centrifuge (Shanghai medical analytical instrument factory), Satrious electronic balance (Germany); Thermostat water bath (Shanghai Yarong Biochemical Instrument Plant); Liquid-transfering gun; , low-temperature and high-speed centrifuge (day beautiful Z323K).
1.3 laboratory animal
Kunming kind male white mouse, body weight 18～22g is provided by China Medicine University's animal center.
2. the preparation of laboratory sample
The panax japonicus total saponins of preparation among the embodiment one.
3. the preparation of test specimen liquid
3.1.CMC-Na the preparation of solution: precision takes by weighing 5gCMC-Na, the 1000mL distilled water is mixed with concentration and is 0.5% CMC-Na solution.
3.2. the preparation of positive control drug simvastatin medicinal liquid: precision takes by weighing 14g simvastatin sheet (containing simvastatin 70mg), the 0.5%CMC-Na suspendible of 100ml, and being made into concentration is the medicinal liquid sample of 0.0007g/ml.
3.3. the preparation of high dose panax japonicus total saponins medicinal liquid: precision takes by weighing the 1.5g panax japonicus total saponins.100ml 0.5%CMC-Na suspendible, being mixed with concentration is the medicinal liquid sample of 0.015g/ml.
3.4. the preparation of low dosage panax japonicus total saponins medicinal liquid: precision takes by weighing the 0.75g panax japonicus total saponins, the 100ml0.5%CMC-Na suspendible, and being mixed with concentration is the medicinal liquid sample of 0.0075g/ml.
4. experimental technique
40 of Kunming mouses, 18-22g, male and female half and half are divided into 4 groups at random, 10 every group.Be divided into normal blank group, simvastatin positive controls, panax japonicus total saponins high dose group, panax japonicus total saponins low dose group.Gastric infusion.Normal group is pressed 0.2ml/10g gavage 0.5%CMCNa every day, administration group gavage every day gives the relative medicine of 0.2ml/10g volume, and dosage is respectively: the simvastatin matched group is that 0.014g/kg, panax japonicus total saponins high dose group are that 0.3g/kg, panax japonicus total saponins low dose group are 0.15/kg.Administration is 14 days altogether.After the fasting 16 hours, in the about 0.5ml of mice eyeground vein clump blood sampling, separation of serum (4000rp/min, 10min, 4 ℃) utilizes kit measurement ALT, AST vigor.
5. result and discussion
The measurement result that table 5. panax japonicus total saponins (Z1) affects ALT (n=10,
)
Annotate:
*Expression has been compared significant difference with normal group, P＜0.05.Together lower.
Table 6. panax japonicus total saponins (Z1) to the measurement result of AST (n=10,
)
The ALT measurement result shows, compares with normal group, and simvastatin, there is significant difference P＜0.05. and illustrate that simvastatin has the hepatic injury effect of significance, panax japonicus total saponins administration group does not then have the hepatic injury effect.
The ASL measurement result shows, compares with normal group, and simvastatin, there is significant difference P＜0.05. and illustrate that simvastatin has the hepatic injury effect of significance, panax japonicus total saponins administration group does not then have the hepatic injury effect.
There are notable difference in panax japonicus total saponins and simvastatin causing aspect the hepatic injury toxic and side effects, and simvastatin has the hepatic injury effect of significance ground, and panax japonicus total saponins is comparatively safe.
Claims (4)
1. panax japonicus total saponins is in the purposes of preparation in the blood lipid-lowering medicine.
2. purposes according to claim 1 is characterized in that described blood fat reducing mainly is by the reducing effect of panax japonicus total saponins to cholesterol, triglyceride and low density lipoprotein, LDL, and the rising effect of high density lipoprotein is reached.
3. purposes according to claim 1 is characterized in that panax japonicus total saponins comprises atherosclerosis that hyperlipidemia and hyperlipidemia cause and the purposes in the medicaments for coronary disease in preparation prevention and treatment.
4. purposes according to claim 1 is characterized in that described medicine comprises panax japonicus total saponins and pharmaceutically acceptable carrier or conventional edible adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010176635 CN102247416B (en) | 2010-05-19 | 2010-05-19 | Blood lipid lowering application of total saponins of panax japonicus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010176635 CN102247416B (en) | 2010-05-19 | 2010-05-19 | Blood lipid lowering application of total saponins of panax japonicus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102247416A CN102247416A (en) | 2011-11-23 |
| CN102247416B true CN102247416B (en) | 2013-03-27 |
Family
ID=44975221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010176635 Active CN102247416B (en) | 2010-05-19 | 2010-05-19 | Blood lipid lowering application of total saponins of panax japonicus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102247416B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101978982B (en) * | 2010-11-17 | 2012-11-28 | 石杨 | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury |
| CN103211828B (en) * | 2013-05-07 | 2015-08-05 | 中国药科大学 | Rhizoma Panacis Japonici saponin IV is preparing the application in blood lipid-lowering medicine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249121A (en) * | 2008-03-24 | 2008-08-27 | 三峡大学 | Panax japonicus total saponins preparation and its applications in medicament for curing myocardial ischemia |
-
2010
- 2010-05-19 CN CN 201010176635 patent/CN102247416B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249121A (en) * | 2008-03-24 | 2008-08-27 | 三峡大学 | Panax japonicus total saponins preparation and its applications in medicament for curing myocardial ischemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102247416A (en) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102247391B (en) | Application of panax japonicus saponin V to reduction of blood fat | |
| CN101401829A (en) | Wild Jinchai liveness extract, preparation and uses thereof | |
| CN102247413B (en) | Hypolipidemic effects of radix dipsaci total saponin and akebia stem saponin D | |
| CN102512438B (en) | Application of pseudostellaria polysaccharide in food for preventing and treating diabetes mellitus as well as health-caring | |
| CN1861637A (en) | Preparation process of Huai Chinese yam polysaccharose and use thereof | |
| CN102224924B (en) | Sea cucumber saponin-containing composition and its application in foods and drugs | |
| CN1788757A (en) | Hyperlipemia-treating Chinese traditional medicinal tablet and its preparation process | |
| CN102247416B (en) | Blood lipid lowering application of total saponins of panax japonicus | |
| WO2013155995A1 (en) | Red yeast and kudzu root pharmaceutical composition for regulating blood lipids and preparation method therefor | |
| CN103585192B (en) | A kind of preparation method of Aleuritopteris argentea (Gmel.) Fee extract and application thereof | |
| CN102247400B (en) | Blood lipid-reducing effect of panax japonicus polysaccharide | |
| CN103211858B (en) | Si-Jun-Zi dropping pill preparation | |
| CN102247418B (en) | Liver protection effect of panax japonicus total saponin and panax japonicus polysaccharide | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN113694104B (en) | Traditional Chinese medicine composition with protection effect on chemical liver injury and liver regeneration promotion function, preparation method and application thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN107485615A (en) | Purposes of the Ligustrum robust glycosides C and combinations thereof in treatment hyperlipidemia and slimming medicine is prepared | |
| CN108065393A (en) | A kind of food or health food prevented and treat cardiovascular and cerebrovascular disease | |
| CN103211828B (en) | Rhizoma Panacis Japonici saponin IV is preparing the application in blood lipid-lowering medicine | |
| CN105168297A (en) | Pharmaceutical composition for treating diabetic nephropathy and preparation method thereof | |
| CN102670698B (en) | The application of Radix Flemingiae Philippinensis extract in preparation control diabetes medicament | |
| CN102247417B (en) | Fat reduction effect of total saponins and polysaccharides of Panax japonicus | |
| CN101664423A (en) | Hypoglycemic active part of osmanthus fragrans, preparation method and application thereof | |
| CN101234103B (en) | Total coumarin angelica dahurica composition | |
| CN103191224A (en) | Liver-protecting function of hedan preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |